CHEN, YI HSING,陈奕兴,陳奕興,TSAI, WAN HUA,蔡宛桦,蔡宛樺,CHEN, YA HUI,陈雅惠,陳雅惠,LAI, CHIH HO,赖志河,賴志河,LIN, YU HSIN,林宥欣
申请号：
TW107125095
公开号：
TW202007401A
申请日:
2018.07.20
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
The present invention provides a pharmaceutical composition used to inhibit gastritis caused by Helicobacter pylori, H. pylori and a food product thereof. The pharmaceutical composition contains lactic acid bacteria selected from the group consisting of Lactobacillus rhamnosus GM-020 (also termed GMNL-74), deposit numbers of BCRC910236 and CCTCC M203098； Lactobacillus acidophilus GMNL-185, deposit numbers of BCRC910774 and CCTCC M2017764； Lactobacillus plantarum GMNL-662, deposit numbers of BCRC910738 and CCTCC M2016571； and the combinations of any two or more thereof.本發明提供一種用於抑制胃幽門螺旋桿菌引發之胃炎的醫藥組合物及食品產品，其包含乳酸菌選自於由鼠李糖乳桿菌(Lactobacillus rhamnosus)GM-020(又稱作GMNL-74)，寄存編號為BCRC910236與CCTCC M203098；嗜酸乳桿菌(Lactobacillus acidophilus)GMNL-185，寄存編號為BCRC910774與CCTCC M2017764以及植物乳桿菌(Lactobacillus plantarum)GMNL-662，寄存編號為BCRC910738與CCTCC M2016571及其任二以上組合的群組。
